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Summary and Discussion 
 
 
Summary of results 
The research presented in this thesis aimed at paving the way for synthetic biology 
applications in Streptococcus pneumoniae. As a starting point, described in Chapter 2, the 
pneumococcal engineering platform PEP was created, which allows for BglBrick assembly of 
genetic components in form of translational units and expression units. The BglBrick 
cloning system was furthermore extended to enable the exchange of ribosome binding sites, 
the addition of N- an C-terminal peptide tags and the assembly of fusion proteins, giving 
rise to the BglFusion format. Three constitutive promoters (P1, P2 and P3) and the Zn2+-
inducible promoter PZ1 were assembled with the reporters luc, gfp and mKate2, and gene 
expression profiles were analyzed. These profiles were displayed, amongst others, in a 
double-logarithmic plot (normalized luminescence versus cell density) to show the growth 
phase dependency of gene expression activity. In Chapter 3, the cloning platform PEP was 
used to assemble a selection platform, consisting of a positive selection marker (erm), a 
negative selection marker (pheS), a population reporter (luc) and a single-cell reporter (gfp). 
This selection platform was used to screen combinatorial promoter libraries, resulting in the 
identification of constitutive promoters of predetermined strength. Furthermore, promoter 
regions were investigated for sequence variability. On the basis of these results, inducible 
promoters harboring operators for the repressors TetR and LacI were created and used to 
assemble gene regulatory networks including inverters, a logic AND gate and toggle 
switches. 
In Chapter 4, studies of the antibiotic growth inhibition of the pneumococcus were 
presented, with a specific interest in the link between inhibition dynamics and the 
bactericidal activity of antimicrobial agents. We found that increasing concentrations of 
bacteriostatic antibiotics decreased the doubling-time of pneumococci immediately from the 
starting point of drug exposure; in contrast, for bactericidal antibiotics, increasing 
concentrations resulted in shortened periods of uninhibited growth before growth 
inhibition took effect. Furthermore, single-cell studies of antibiotic treatment were 
presented, and these studies elucidated, amongst others, that pneumococcal heteroresistance 
towards cell wall synthesis inhibitors develops upon induction, and in competition with 
ongoing cell lysis. Both cell-to-cell variability in antibiotic susceptibility and continuous 
gene expression activity during drug exposure were demonstrated to impact resistance 
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development. In Chapter 6, a special characteristic of chloramphenicol resistance was 
investigated. We showed that the microbial context during infectious disease can 
compromise chloramphenicol therapy. In an environment containing CAT-expressing cells 
chloramphenicol becomes gradually deactivated via intracellular acetylation, resulting in the 
depletion of the antibiotic. Finally, in Chapter 7, the dynamics of switching events of 
bistable systems was assayed, on the basis of the lac-pathway in Escherichia coli. With the 
help of mathematical modelling, the rate-limiting fluctuations underlying switching events 
from the un-induced to the induced state were identified. Single-cell switching was shown 
to depend on the time period over which LacI repressor, after promoter dissociation, 
remains unbound from the lac promoter. 
 
Synthetic biology applications of the pneumococcus 
Synthetic biology aims at reprogramming biological systems, and at engineering organisms 
towards novel functionalities and new applications. In the context of the human pathogen 
S. pneumoniae, engineering attempts might pursue several goals. The proximate goal of 
pneumococcal engineering could represent support for fundamental research, such as to 
enable studies of gene expression patterns of higher complexity. The expression of virulence 
factors, for example, is regulated by multifactorial cues and can result in complex patterns 
including population bifurcations. The ability to reengineer such circuits would allow for in 
vivo studies of the importance of gene expression control on the pathogenicity of S. 
pneumoniae, an endeavor that was a major inspiration for this thesis (Chapters 2 and 3). The 
distal goal of pneumococcal engineering, to date merely a vision and a technological utopia, 
could be found in species-wide genome engineering attempts: the infiltration of S. 
pneumoniae by a genetic program that reduces pneumococcal pathogenicity. Engineering 
the genome of a human commensal (and opportunistic pathogen), also referred to as 
microbiome engineering1,2, raises many questions, of ethical nature, concerning human and 
environmental safety, and of technical feasibility. In the following, these issues shall be 
discussed in more detail, with a keen focus on the case of the pneumococcus. 
The eradication of infectious disease is an ambitious goal that requires a global action 
plan, and these initiatives are spearheaded by the World Health Organization (WHO) 
which is an agency within the United Nations. The biggest success story to date is the 
Smallpox Eradication Program (1966-1980), resulting in the elimination of the disease in 
1979. Current programs include the Global Polio Eradication Initiative (since 1988), while 
the Global Malaria Eradication Campaign was dropped in the 1970s because it was 
considered too ambitious. Requirements for the ability to eradicate a disease include the  
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absence of a non-human reservoir, the availability of effective clinical interventions, the 
ability to clearly identify carriers and the presence of a critical community size below which 
the pathogen ceases to circulate3. In the case of the pneumococcus, only the first two criteria 
are fulfilled. However, eradicating the pneumococcus might be far more difficult than 
limiting or eliminating its pathogenicity. Microbiome engineering could allow for such 
measures, and the field of synthetic biology might develop and provide this technology in 
the near future. 
In parallel to technical advances, a bioethics debate is required. The question ‘To what 
extent is it justifiable to actively intervene in the evolution of a species?’ was answered in the 
past with a strong bias depending on the species, as exemplified by protection initiatives, 
such as the International Union for the Conservation of Nature (IUCN) Red List of 
endangered species, in contrast to the mentioned eradication initiatives by the WHO. A 
more difficult to answer question is ‘How to weigh the benefits of microbiome engineering 
against potentially unpredictable negative consequences for human health and the 
environment, and which conflicts of interest must be taken into consideration?’. For the 
example of S. pneumoniae, with its high genomic plasticity, one could argue that 
anthropogenic microbiome manipulation already takes place for decades, by inadvertently 
selecting for antibiotic resistance and against vaccine serotypes (the rise of antibiotic 
resistance following widespread antibiotic usage and the changes of the composition of 
prevailing serotypes following large-scale PCV vaccination trials are discussed in Chapter 1). 
Nevertheless, microbiome engineering would represent a new dimension of human 
intervention, characterized by a more conscious and more goal-oriented manipulation, and 
furthermore by an execution on a shorter time scale. 
The discussion of ethical issues of microbiome engineering will likely show similarities 
to the debate about genetically modified organisms (GMOs) in food, and the example 
discussed above (inadvertent versus conscious microbiome manipulation) resembles the 
appointed boundary between traditional breeding methods and GMO technologies. A 
distinguishing factor is that the spreading of GMO plants can be contained, within limits, 
and furthermore that products can be labeled and thus also chosen against by consumers. A 
genetically engineered microbiota, in contrast, would be more difficult to contain, resulting 
in an incapacitation of individuals whether to support this technology or not. However, the 
public opinion and support concerning GMOs might differ between red (medical) 
biotechnology applications and green (agricultural) biotechnology applications, depending 
on factors such as the verifiable and perceived benefit of the technology, transparency of the 
debate, education of the public, etc. 
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Benefits of microbiome engineering 
The human microbiota, which is the aggregate of microorganisms residing on the skin, on 
the mucosa and in the gastrointestinal tract, is the result of eons of host-symbiont co-
evolution. There is increasing awareness that the presence of an intact microbiota plays a 
crucial role for human health and wellbeing. The gut microbiota, for example, contributes 
to metabolic processes by breaking down nutrients that humans cannot digest. The 
commensal microbiota on epithelial surfaces contributes to the first line of defense against 
pathogens, both passively by imposing niche competition and actively via the production of 
antimicrobial peptides. Importantly, the presence of an intact microbiota guarantees regular 
communication between foreign cells and the immune system, which is believed to 
represent an essential contributing factor for the priming of immune responses4,5. The 
dramatic changes of human ecology during the last century, including improved sanitary 
conditions and clinical interventions, likely caused disturbances to the evolved co-existence 
of humans and their microbiota6,7. 
People in modern society struggle from thitherto uncommon immune pathologies, 
such as allergic disease and autoimmune disorder including type 1 diabetes and multiple 
sclerosis8. There is evidence that these phenomena are associated to alterations of the 
microbiota, caused by an impaired horizontal transfer, the hygiene hypothesis9, and/or by 
an impaired vertical transfer, the disappearing microbiota hypothesis6. For example, the 
progressive disappearance of the human commensal and opportunistic pathogen Heliobacter 
pylori from its gastric niche was shown to be linked to increases of esophageal cancer and 
allergic asthma10. The importance of symbionts for immune maturation could also be 
demonstrated on the basis of animal models; germ-free mice were shown to exhibit defective 
T and B cells in the mucosa, reduced T helper cells in peripheral lymphoid organs and 
diminished levels of IgG and IgA4. Interestingly, all of these immune deficiencies could be 
reversed by microbial colonization4. 
Modern clinical interventions, in specific antibiotic therapy and vaccination, 
represented a revolution for human health. However, in the context of a more 
comprehensive health perspective, it might be necessary to reevaluate the unintended 
consequences of these interventions, such as the long-term effect of broad-spectrum 
antibiotic therapy on the microbiota or the alteration of the bacterial carriage after 
vaccination11. To date, these clinical interventions are without alternative. Microbiome 
engineering, and in specific the engineering of an opportunistic pathogen towards reduced 
pathogenicity, might represent such an alternative, by solving a problem before it comes 
into existence. In this context, clinical interventions could become largely unnecessary and 
would only need to be applied in rare cases of infectious disease caused by non-
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opportunistic pathogens. Reduced antibiotic usage, in turn, would not only allow for fewer 
disturbances of the microbiota, but furthermore contribute to the rehabilitation of effective 
antibiotic therapy (see Chapter 1). 
Misusage of antibiotics during the last decades has resulted in the rise of antibiotic 
resistance, which is on the verge of becoming a serious threat for human health12. This issue 
is especially problematic because of a lack of new antimicrobial agents on the market, and 
the search for new drugs remains an urgent task. However, even for drugs that were not 
discovered to date, resistance mechanisms already exist that will eventually spread. In all 
likelihood, it will be difficult to generate a sustainable system for antibiotic therapy, in 
which a specific antibiotic remains effective for a long period of time. Consequentially, new 
agents will need to be discovered and new therapies will need to be developed on a regular 
basis, in line with Lewis Carroll’s Red Queen’s race that ‘it takes all the running you can do 
to keep in the same place’. Microbiome engineering might represent a game changer to this 
race. Importantly, the technology could not only solve the issue of spreading resistance, but 
also overcome another major limitation of current clinical interventions: the limited access 
to antibiotic therapy and vaccinations of third-world country residents. 
 
How to evolve the pneumococcus 
Actively influencing the microbiota, although still controversial, has become an increasingly 
common therapeutic intervention, such as fecal microbiota transplants or the ‘seeding’ of 
newborns after C-section with vaginal swaps13–16. However, in some cases, it might not be 
possible to replace the ‘bad bacteria’ by the ‘good bacteria’, because of evolutionary fitness 
constraints. Pathogens might thrive because of the very characteristic of being pathogenic, 
for example when sterile tissue can be accessed or when disease symptoms increase the host-
to-host spreading (note that disease symptoms are often caused by the immune response, 
and not by the pathogen itself)17. In the field of evolutionary biology, virulence was initially 
considered to represent the artifact of an evolutionary recent association between a host and 
a parasite18. The reasoning behind this hypothesis was that harming the host, in the long 
run, would also harm the parasite depending on the host, and co-evolution should 
consequently drive the relationship towards commensalism. However, in more recent years, 
other hypothesis have been made which suggest that virulence, under certain conditions, 
can be maintained in the course of co-evolution18–21. 
The association between humans and S. pneumoniae is believed to date back a long 
time, as evidenced by the appearance of iga in response to the emerging immunoglobulin 
A1 (IgA1) subclass in the common lineage of humans, chimpanzees and gorillas22. This 
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raises the question why the pneumococcus, despite its long history of human association, 
did not lose its pathogenicity. Investigations of streptococcal evolution showed that the 
common ancestor of Streptococcus pneumoniae and its close relative Streptococcus mitis likely 
resembled the present-day pneumococcus22. Ancestral strains thus indeed have developed 
towards reduced virulence allowing for long-term carriage, giving rise to the non-pathogenic 
S. mitis. However, a second strategy seems to have proven successful, the ability to gain high 
genomic plasticity, resulting in S. pneumoniae23. The characteristic of high genomic 
plasticity enables the pneumococcus to reinfection individuals that have developed humoral 
immunity, provided that this immunity targets a different serotype. The fact that both 
strategies (decreased virulence and high genomic plasticity) developed in parallel indicates 
that different ecological niches have been occupied, disqualifying S. mitis as candidate for 
replacing S. pneumoniae. 
Other contributing factors for the apparent present-day virulence of S. pneumoniae 
might be found in recent changes within the human host population, such as increased 
lifespans accompanied by a fading responsiveness of the immune system or decreased 
mortality of individuals with a weak immune systems because of clinical interventions. 
Regardless, pneumococcal virulence does not seem to represent a last remainder of an 
evolutionary adaptation process towards commensalism; the ability to induce and resist 
mucosal inflammations likely represents a fitness advantage that outweighs the negative 
consequence of a subsequent humoral immunity. This fitness advantage could be found, for 
example, in the clearance of niche competitors or in increased spreading via the stimulation 
of secretion production (Chapter 1). Causing systemic disease, however, does not contribute 
to pneumococcal spreading and rather represent a collateral damage that imposes a fitness 
burden (Chapter 1). Nevertheless, S. pneumoniae maintained its pathogenicity to date, 
indicating that the current lifestyle is a successful strategy that places the organism at a local 
peak within its evolutionary fitness landscape. 
It seems unlikely that S. pneumoniae, on the time scale of decades, will be replaced 
from its ecological niche or that the organism will evolve towards reduced pathogenicity. 
Nevertheless, it appears reasonable to assume that the current pneumococcal colonization 
strategy that is accompanied by opportunistic pathogenicity can be improved, both from the 
perspective of humans (reduced morbidity and mortality of carriers) and from the 
perspective of S. pneumoniae (increased spreading via healthy carriers). Microbiome 
engineering could represent a way to fast-track such an evolution, and thus to bridge a 
valley in the fitness landscape of the pneumococcus, by infiltrating the organism with a 
synthetic genetic program. This program needs to fulfill three criteria: (i) reduce the 
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pathogenicity, the main goal; (ii) increase the fitness, to establish the program; (iii) 
intrinsically tie these two traits. The ability to cause mucosal inflammations of the 
nasopharynx should be maintained, while preventing from systemic infections, and evolved 
pneumococci carrying the genetic program need to be able to outcompete their pathogenic 
ancestors. 
Preventing from systemic disease should represent a fitness advantage by itself, and one 
could, for example, construct a program on the basis of a toxin-antitoxin system, whereat 
the antitoxin is exclusively expressed in the nasopharynx. Such a network would show a 
similar functionality as tumor suppressor genes in mammalian cells, by preventing from 
harm caused by misguided individual cells to the overall cell population. Instead of 
responding to the location, one could also construct a system that monitors the 
responsiveness of the immune system, and that regulates virulence factor expression 
accordingly. Launching such programs likely imposes a manageable risk for human and 
environmental safety. However, the fitness increase accompanied by decreased human 
morbidity and mortality might not be sufficient for a species-wide establishment of such 
regulatory circuits. A direct advantage within the nasopharynx might be required, especially 
when considering the case of mixed infections (modified and non-modified pneumococci), 
to overcome the burden imposed by the expression and maintenance of the genetic 
program. 
The fitness increase required for the spreading of a synthetic regulatory network could 
be enhanced in different ways, for example by antimicrobial peptide expression or via an 
external regulation on the basis of antibiotic resistance. However, it would be difficult to 
intrinsically tie such factors to a mechanism for reduced pathogenicity, and the two genetic 
traits might eventually uncouple. These programs consequently represent a high risk for 
human health and may give rise to unpredictable consequences. In any case, the discussed 
strategies will need to be examined with extreme care, by in vitro studies, animal infection 
models and mathematical modeling. Furthermore, transmission methods enabling 
horizontal gene transfer need to be inquired, a task that S. pneumoniae, with its high 
genomic plasticity and the ability to develop natural competence, might be well suited for. 
Together, the discussed preconditions for a reasonable implementation of microbiome 
engineering meet many of the characteristics of the pneumococcus, making the organism a 
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